One injection every two months is all people with HIV and those on PrEP may need in the not-to-distant future. The injectable drug Cabotegravir appears to be 69 percent more effective than Truvada, the daily pill most commonly prescribed.
According to Science magazine, 4,500 people participated in the study. Divided into four equal groups, each participant was randomly assigned to receive a Cabotegravir injection, a placebo injection, Truvada or a Truvada placebo.